1220701-21-2

Upstream product

• 1220701-19-8 C₁₆H₁₆N₆O₃ 

Downstream Products

• 1220701-37-0 (S)-N-(4-(1-(2-(2-hydroxypropylamino)pyrimidin-4-yl)-1H-imidazol-2-yl)phenyl)-4-morpholino-3-(trifluoromethyl)benzamide 
• 1220701-35-8 C₂₈H₂₂ClF₃N₆O₃ 
• 1220701-36-9 C₂₅H₂₂N₈O₂S 
• 1220701-31-4 C₂₄H₂₀ClF₃N₆O₂ 
• 1220701-34-7 C₂₈H₂₆N₆O₄ 
• 1220701-44-9 (S)-1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(4-(1-(2-(2-hydroxypropylamino)pyrimidin-4-yl)-1H-imidazol-2-yl)phenyl)urea 
• 1220701-45-0 (S)-1-(3,4-dichlorophenyl)-3-(4-(1-(2-(2-hydroxypropylamino)pyrimidin-4-yl)-1H-imidazol-2-yl)phenyl)urea 
• 1220701-47-2 C₂₃H₂₂ClN₇O₂ 
• 1220701-46-1 (S)-1-(4-(1-(2-(2-hydroxypropylamino)pyrimidin-4-yl)-1H-imidazol-2-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea 
• 1220701-32-5 (S)-N-(4-(1-(2-(2-hydroxypropylamino)pyrimidin-4-yl)-1H-imidazol-2-yl)phenyl)-3-morpholino-5-(trifluoromethyl)benzamide 

Relevant academic research and scientific papers

Discovery and initial SAR of pyrimidin-4-yl-1H-imidazole derivatives with antiproliferative activity against melanoma cell lines

The synthesis of a novel series of pyrimidin-4-yl-1H-imidazol-2-yl derivatives 7, 8, 9 and their antiproliferative activities against A375P human melanoma cell line and WM3629 cell line were described. Most compounds showed superior antiproliferative activities compared to Sorafenib, the well-known RAF inhibitor. Among them, 7a exhibited potent activities on both cell lines (IC50 = 0.62 and 4.49 μM, respectively) and turned out to be a selective and potent CRAF inhibitor.